Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific literature. Landmark cutting-edge science and clinical trial data based on Natera’s suite of products have been published in top journals, such as Science, Nature, Nature Medicine, and New England Journal of